AdaptHealth Corp - 1782060 - ADAPTHEALTH CORP

Explicit Guidance:

• Margins: Kaiser Permanente contract exited Q3 2024 at a 14% run rate; target to reach 20% margin by late 2027.
• Cost Reduction: Diabetes segment sale to Cardinal Health is expected to eliminate approximately $30 million in costs over 2027, with the majority realized within the first 12 months if the deal closes in Q1 2027.
• Leverage: Net leverage is currently at 3.0x; company reaffirms target to reduce to 2.5x using proceeds from the Diabetes sale and subsequent free cash flow.
• MyApp Users: Target to increase user base to 2 million by the end of 2026.
• Financial Impact: Medline field action costs have been baked into the Q4 guidance at the low end; expected to be a timing/cost issue rather than a material P&L driver.

Business-Segment Outlook:

• West Coast Expansion: Strategic focus for 2027 to leverage the existing Kaiser infrastructure and 40 new locations; "halo effect" expected in H2 2027 to capture non-Kaiser business (salespeople entering footprint) without significant incremental capex as capacity sits idle.
• Core Business Growth: Organic base business grew 4% YTD; 2027 outlook for true comps and straight-line growth after lapping 2026's transformational activity.
• Capitated Contracts: Pipeline of additional capitated deals is strong, particularly with West Coast payers; margins expected to be "at or better" than enterprise average due to predictable cash flows and low administrative costs.
• Diabetes Segment: Portfolio pruning completed; segment to be sold to Cardinal Health in H1 2027, leaving the company focused exclusively on sleep, respiratory, and wellness-at-home supplies.
• Respiratory/Sleep: End markets are strong; focus on maintaining fee-for-service while expanding capitated and enterprise preferred provider agreements.

Market and Competitive Outlook:

• Competition: Anticipation of a new entrant in the sleep space (ResMed injunction clearing required); company views increased competition as beneficial for leverage regarding pricing and volume with suppliers like ResMed.
• Industry Dynamics: Benefiting from payer consolidation (network consolidation) which favors large, technologically sophisticated providers; competitors with less mature tech infrastructure face disadvantages in billing, risk, and disaster recovery capabilities.
• Market Share: Company intends to maintain market share through service quality and "blocking and tackling" rather than aggressive price shifts or disruptive M&A; no transformative M&A planned for the near term, though opportunistic "resupply patient" acquisitions are possible.
• Supply Chain: Secured "front of the line" status with Medline for bed replacements; diversifying supply chain to mitigate risks from field actions and ensuring capacity to meet demand during shortages.

Macro / Industry Outlook:

• Regulatory: Medicare billing number moratorium (announced Feb 2026) lifted; pending full approval to enable "halo effect" expansion in H2 2027.
• Competitive Bid: Company believes it has sidestepped competitive bidding risks through previous portfolio pruning (selling diabetes/low-margin assets) to focus on sleep and respiratory markets.
• Technology Infrastructure: Oracle, BrightTree, Snap, and Snowflake layers fully deployed; no further major ERP/tech investments required, allowing capital allocation toward growth.

Strategic Initiatives:

• Kaiser Renegotiation: Active negotiations to "right-size" the financial profile (jump-off point) ahead of schedule; target completion by end of calendar year to secure budget certainty.
• Operations Standardization: Continued maturation of "standard work" and supply chain discipline (e.g., drop-shipping) expected to yield labor and OpEx reductions throughout 2027.
• Capital Allocation: At 2.5x leverage target, future capital will be balanced between debt pay-down, opportunistic M&A (focused on patient resupply networks, not brick-and-mortar), and potential share buybacks.
• Enterprise Sales: Established strategic accounts initiative to sign preferred provider agreements with large health systems quarterly.

Risks and Headwinds to Outlook:

• Kaiser Baseline: Initial utilization data gaps led to underestimating demand and "pent-up demand" surges; margin target depends on successful renegotiation of the utilization baseline.
• Stranded Costs: Approximately $20 million of the $30 million in post-sale cost reductions are "true stranded costs" that will take time to grow through rather than immediate elimination; offset strategy relies on organic growth over the next two years.
• Supplier Volatility: Risks regarding ResMed pricing/terms remain if new market entrants alter supply dynamics, though company is actively negotiating to ensure inventory availability.
• Medline Field Action: Potential supply constraints for bed replacements could impact timing and incurring upfront costs, though managed via secured front-line status.

Management Tone on the Future:

• Confidence: Management expresses high confidence in 2027, characterizing it as an "exciting," "calming," and "straight down the fairway" year.
• Shift in Narrative: Transitioning from a "transformational" year (fixing Kaiser, pruning portfolio) to a "continuous improvement" and "blocking and tackling" phase.
• Operational Maturity: CEO compares operations maturity to moving from "kindergarten to middle school," noting significant progress in standardizing work and leveraging technology.
• Stability: Leadership team stability (Harris joining Sept) and resolved structural issues are viewed as foundational for predictable 2027 performance.

Miscellaneous:

• ResMed Dispute: Resolved within the quarter; back to "normal course of business" with tiered rebates restored for Q3/Q4, with ongoing negotiations for the following year.
• Acquisition Philosophy: Shift away from "roll-up" M&A toward acquiring patient care networks/resupply capabilities; footprint considered solid with minor "holes" in the West Coast to fill.